| DISTRIBUTOR-A |
DISTRIBUTOR-A |
90%
|
For the three months ended March 31, 2026, distributor A accounted for approximately 14 % of the Company’s revenue. |
| FRESENIUS-MEDICAL-CARE |
FRESENIUS-MEDICAL-CARE |
90%
|
In August 2022, we expanded our partnership with Fresenius Medical Care to a global marketing collaboration. |
| DISTRIBUTOR-B |
DISTRIBUTOR-B |
85%
|
As of March 31, 2026, distributor A and distributor B accounted for approximately 17 % and 11 %, respectively, of the Company’s outstanding accounts receivable. |
| FMS |
Fresenius Medical Care AG |
85%
|
Reciprocal relationship from FMS graph: Reciprocal relationship from CTSO graph: Reciprocal relationship from FMS graph: Reciprocal relationship from CTSO graph: Reciprocal relationship from FMS grap… |
| FMS |
Fresenius Medical Care AG |
85%
|
d registration, due to other factors such as market adoption, reimbursement and/or geopolitical developments. We continuously evaluate other potential distributor and strategic partner networks in ot… |
| FRESENIUS-MEDICAL-CARE-AG-B-BRAUN-AVITUM-AG |
FRESENIUS-MEDICAL-CARE-AG-B-BRAUN-AVITUM-AG |
85%
|
rsement and/or geopolitical developments. We continuously evaluate other potential distributor and strategic partner networks in other countries that accept CE Mark approval. In addition to our direc… |
| TERUMO-CARDIOVASCULAR-GROUP |
TERUMO-CARDIOVASCULAR-GROUP |
85%
|
senius Medical Care AG, B. Braun Avitum AG, Aferetica s.r.l., and Terumo Cardiovascular Group. |
| AFERETICA-S-R-L |
AFERETICA-S-R-L |
80%
|
senius Medical Care AG, B. Braun Avitum AG, Aferetica s.r.l., and Terumo Cardiovascular Group. |
| B-BRAUN-AVITUM-AG |
B-BRAUN-AVITUM-AG |
80%
|
senius Medical Care AG, B. Braun Avitum AG, Aferetica s.r.l., and Terumo Cardiovascular Group. |
| SENIUS-MEDICAL-CARE-AG |
SENIUS-MEDICAL-CARE-AG |
80%
|
senius Medical Care AG, B. Braun Avitum AG, Aferetica s.r.l., and Terumo Cardiovascular Group. |
| AVENUE-CAPITAL-GROUP |
AVENUE-CAPITAL-GROUP |
62%
|
s to an additional aggregate $ 2.5 million (“Tranche 2b”) from Avenue Capital Group and receive a further six-month extension of the interest only period to the July 1, 2027 maturity date, subject to… |
| CYTOSORBENTS-EUROPE-GMBH |
CYTOSORBENTS-EUROPE-GMBH |
62%
|
ousands unless otherwise stated. Prior periods have been adjusted accordingly for consistent presentation. Certain prior year amounts in the footnotes have been reclassified to conform to the current… |
| CYTOSORBENTS-MEDICAL-CANADA-INC |
CYTOSORBENTS-MEDICAL-CANADA-INC |
62%
|
ousands unless otherwise stated. Prior periods have been adjusted accordingly for consistent presentation. Certain prior year amounts in the footnotes have been reclassified to conform to the current… |
| CYTOSORBENTS-MEDICAL-INC |
CYTOSORBENTS-MEDICAL-INC |
62%
|
ousands unless otherwise stated. Prior periods have been adjusted accordingly for consistent presentation. Certain prior year amounts in the footnotes have been reclassified to conform to the current… |
| CYTOSORBENTS-MEDICAL-UK-LIMITED |
CYTOSORBENTS-MEDICAL-UK-LIMITED |
62%
|
ousands unless otherwise stated. Prior periods have been adjusted accordingly for consistent presentation. Certain prior year amounts in the footnotes have been reclassified to conform to the current… |
| CYTOSORBENTS-SWITZERLAND-GMBH |
CYTOSORBENTS-SWITZERLAND-GMBH |
62%
|
ousands unless otherwise stated. Prior periods have been adjusted accordingly for consistent presentation. Certain prior year amounts in the footnotes have been reclassified to conform to the current… |
| CYTOSORBENTS-UK-LIMITED-CYTOSORBENTS-INDIA-PRIVA |
CYTOSORBENTS-UK-LIMITED-CYTOSORBENTS-INDIA-PRIVA |
62%
|
ousands unless otherwise stated. Prior periods have been adjusted accordingly for consistent presentation. Certain prior year amounts in the footnotes have been reclassified to conform to the current… |
| FIELD-READY-BLOOD-GROUP |
FIELD-READY-BLOOD-GROUP |
62%
|
specializes in the sale of certain medical products and devices, specifically extracorporeal therapies, in the critical care, cardiac surgery and liver disease markets (“Aferetica”). The agreement wa… |
| FRESNEIUS-MEDICAL-CARE-AG |
FRESNEIUS-MEDICAL-CARE-AG |
62%
|
country distribution and/or co-marketing agreements with Fresneius Medical Care AG dating back to December 2014. Over the years, these agreements have included partnerships to support the commerciali… |
| ROKK-LLC |
ROKK-LLC |
62%
|
specializes in the sale of certain medical products and devices, specifically extracorporeal therapies, in the critical care, cardiac surgery and liver disease markets (“Aferetica”). The agreement wa… |
